Email
Location
- Proof of concept (2023) — reMARK-AML: Re-envisioning risk biomarkers in acute myeloid leukemia (AML) at single-cell level
- Consolidator (2016) — ContraNPM1AML: Dissecting to hit the therapeutic targets in nucleophosmin (NPM1)-mutated acute myeloid leukemia